{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000073","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.446514+00:00","generated_at":"2026-05-28T17:59:13.865018+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"ADMA Biologics appoints Eduardo Rene Salas to Board of Directors","bullets":["Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.","Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).","He currently serves on audit committee of Intra-Cellular Therapies (since 2022).","He will receive initial grant of options to purchase 20,011 shares of common stock.","No material transactions or arrangements in connection with appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000073","json":"https://secwatch.observer/filing/0001140361-25-000073.json","markdown":"https://secwatch.observer/filing/0001140361-25-000073.md","text":"https://secwatch.observer/filing/0001140361-25-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/ef20040947_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T17:59:13.865018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c1b2ad927","claim":"Eduardo Rene Salas was appointed as Class I Director at ADMA BIOLOGICS, INC..","evidence_excerpt":"On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}